We’re not in it for the money—lay people’s moral intuitions on commercial use of ‘their’ biobank

Medicine Health Care and Philosophy (Impact Factor: 0.91). 01/2013; 16(2):1-12. DOI: 10.1007/s11019-011-9353-9
Source: PubMed

ABSTRACT Great hope has been placed on biobank research as a strategy to improve diagnostics, therapeutics and prevention. It seems
to be a common opinion that these goals cannot be reached without the participation of commercial actors. However, commercial
use of biobanks is considered morally problematic and the commercialisation of human biological materials is regulated internationally
by policy documents, conventions and laws. For instance, the Council of Europe recommends that: “Biological materials should
not, as such, give rise to financial gain”. Similarly, Norwegian legislation reads: “Commercial exploitation of research participants,
human biological material and personal health data in general is prohibited”. Both articles represent kinds of common moral
intuitions. A problem, however, is that legislative documents are too vague and provide room for ample speculation. Through
the use of focus group interviews with Norwegian biobank donors, we have tried to identify lay intuitions and morals regarding
the commercial use of biobanks. Our findings indicate that the act of donation and the subsequent uses of the samples belong
to two different spheres. While concerns around dignity and commodification were present in the first, injustice and unfairness
were our informants’ major moral concerns in the latter. Although some opposition towards commercial actors was voiced, these
intuitions show that it is possible to render commercial use of biobanks ethically acceptable based on frameworks and regulations
which hinder commodification of the human body and promote communal benefit sharing.

KeywordsBenefit sharing–Biobanking–Commercialisation–Commodification–Focus group research–Lay perspective

  • [Show abstract] [Hide abstract]
    ABSTRACT: Access to human bioresources is essential to the understanding of human diseases and to the discovery of new biomarkers aimed at improving the diagnosis, prognosis, and the predictive response of patients to treatments. The use of biospecimens is strictly controlled by ethical assessment, which complies with the laws of the country. These laws regulate the partnerships between the biobanks and industrial actors. However, private-public partnerships (PPP) can be limiting for several reasons, which can hamper the discovery of new biological tests and new active molecules targeted to human diseases. The bottlenecks and roadblocks in establishing these partnerships include: poor organization of the biobank in setting up PPP, evaluation of the cost of human samples, the absence of experience on the public side in setting up contracts with industry, and the fact that public and private partners may not share the same objectives. However, it is critical, in particular for academic biobanks, to establish strong PPP to accelerate translational research for the benefits of patients, and to allow the sustainability of the biobank. The purpose of this review is to discuss the main bottlenecks and roadblocks that can hamper the establishment of PPP based on solid and trusting relationships.
    Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 12/2013; · 2.56 Impact Factor
  • Source
    Croatian Medical Journal 10/2013; 54(5):496-500. · 1.25 Impact Factor
  • Biopreservation and Biobanking 12/2013; 11(6):397-8. · 1.50 Impact Factor

Full-text (2 Sources)

Available from
May 21, 2014